Logo image of UTHR

UNITED THERAPEUTICS CORP (UTHR) Stock Fundamental Analysis

NASDAQ:UTHR - Nasdaq - US91307C1027 - Common Stock - Currency: USD

367.36  -13.42 (-3.52%)

Premarket: 369.51 +2.15 (+0.59%)

Fundamental Rating

7

Taking everything into account, UTHR scores 7 out of 10 in our fundamental rating. UTHR was compared to 571 industry peers in the Biotechnology industry. UTHR has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. An interesting combination arises when we look at growth and value: UTHR is growing strongly while it also seems undervalued. With these ratings, UTHR could be worth investigating further for value and growth and quality investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

UTHR had positive earnings in the past year.
In the past year UTHR had a positive cash flow from operations.
Of the past 5 years UTHR 4 years were profitable.
UTHR had a positive operating cash flow in 4 of the past 5 years.
UTHR Yearly Net Income VS EBIT VS OCF VS FCFUTHR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M 1B

1.2 Ratios

With an excellent Return On Assets value of 15.60%, UTHR belongs to the best of the industry, outperforming 97.69% of the companies in the same industry.
The Return On Equity of UTHR (18.21%) is better than 96.98% of its industry peers.
UTHR has a better Return On Invested Capital (16.59%) than 97.51% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for UTHR is in line with the industry average of 13.95%.
The 3 year average ROIC (12.87%) for UTHR is below the current ROIC(16.59%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 15.6%
ROE 18.21%
ROIC 16.59%
ROA(3y)11.66%
ROA(5y)8.69%
ROE(3y)14.55%
ROE(5y)11.01%
ROIC(3y)12.87%
ROIC(5y)12.67%
UTHR Yearly ROA, ROE, ROICUTHR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 20 30 40

1.3 Margins

Looking at the Profit Margin, with a value of 40.31%, UTHR belongs to the top of the industry, outperforming 98.76% of the companies in the same industry.
UTHR's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 48.91%, UTHR belongs to the top of the industry, outperforming 99.82% of the companies in the same industry.
In the last couple of years the Operating Margin of UTHR has remained more or less at the same level.
UTHR has a better Gross Margin (88.94%) than 92.18% of its industry peers.
In the last couple of years the Gross Margin of UTHR has remained more or less at the same level.
Industry RankSector Rank
OM 48.91%
PM (TTM) 40.31%
GM 88.94%
OM growth 3Y8.46%
OM growth 5Y0.63%
PM growth 3Y6.83%
PM growth 5Y3.17%
GM growth 3Y-1.38%
GM growth 5Y0.26%
UTHR Yearly Profit, Operating, Gross MarginsUTHR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40 60 80

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so UTHR is still creating some value.
The number of shares outstanding for UTHR has been increased compared to 1 year ago.
Compared to 5 years ago, UTHR has more shares outstanding
Compared to 1 year ago, UTHR has an improved debt to assets ratio.
UTHR Yearly Shares OutstandingUTHR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
UTHR Yearly Total Debt VS Total AssetsUTHR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2B 4B 6B

2.2 Solvency

An Altman-Z score of 12.52 indicates that UTHR is not in any danger for bankruptcy at the moment.
UTHR has a better Altman-Z score (12.52) than 88.81% of its industry peers.
There is no outstanding debt for UTHR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.45
Altman-Z 12.52
ROIC/WACC1.74
WACC9.56%
UTHR Yearly LT Debt VS Equity VS FCFUTHR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2B 4B

2.3 Liquidity

UTHR has a Current Ratio of 4.58. This indicates that UTHR is financially healthy and has no problem in meeting its short term obligations.
UTHR has a Current ratio of 4.58. This is comparable to the rest of the industry: UTHR outperforms 50.27% of its industry peers.
UTHR has a Quick Ratio of 4.41. This indicates that UTHR is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of UTHR (4.41) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.58
Quick Ratio 4.41
UTHR Yearly Current Assets VS Current LiabilitesUTHR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 1B 2B 3B

More info and screens

8

3. Growth

3.1 Past

UTHR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.45%, which is quite impressive.
UTHR shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.08% yearly.
UTHR shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.04%.
Measured over the past years, UTHR shows a small growth in Revenue. The Revenue has been growing by 7.41% on average per year.
EPS 1Y (TTM)25.45%
EPS 3Y19.66%
EPS 5Y8.08%
EPS Q2Q%18.77%
Revenue 1Y (TTM)25.04%
Revenue growth 3Y16.2%
Revenue growth 5Y7.41%
Sales Q2Q%22.89%

3.2 Future

UTHR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.25% yearly.
The Revenue is expected to grow by 11.32% on average over the next years. This is quite good.
EPS Next Y27.89%
EPS Next 2Y19.32%
EPS Next 3Y14.52%
EPS Next 5Y22.25%
Revenue Next Year25.46%
Revenue Next 2Y17.71%
Revenue Next 3Y13.85%
Revenue Next 5Y11.32%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
UTHR Yearly Revenue VS EstimatesUTHR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B
UTHR Yearly EPS VS EstimatesUTHR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20 40 60

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 16.13, the valuation of UTHR can be described as correct.
96.27% of the companies in the same industry are more expensive than UTHR, based on the Price/Earnings ratio.
UTHR is valuated rather cheaply when we compare the Price/Earnings ratio to 30.30, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 13.01, which indicates a correct valuation of UTHR.
Based on the Price/Forward Earnings ratio, UTHR is valued cheaply inside the industry as 96.80% of the companies are valued more expensively.
UTHR's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.06.
Industry RankSector Rank
PE 16.13
Fwd PE 13.01
UTHR Price Earnings VS Forward Price EarningsUTHR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of UTHR indicates a rather cheap valuation: UTHR is cheaper than 98.58% of the companies listed in the same industry.
UTHR's Price/Free Cash Flow ratio is rather cheap when compared to the industry. UTHR is cheaper than 96.80% of the companies in the same industry.
Industry RankSector Rank
P/FCF 18.26
EV/EBITDA 8.27
UTHR Per share dataUTHR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80 100

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
UTHR has an outstanding profitability rating, which may justify a higher PE ratio.
UTHR's earnings are expected to grow with 14.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.58
PEG (5Y)2
EPS Next 2Y19.32%
EPS Next 3Y14.52%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for UTHR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UNITED THERAPEUTICS CORP

NASDAQ:UTHR (2/20/2025, 8:00:01 PM)

Premarket: 369.51 +2.15 (+0.59%)

367.36

-13.42 (-3.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19 2025-02-19/amc
Earnings (Next)04-29 2025-04-29/amc
Inst Owners105.66%
Inst Owner Change42.27%
Ins Owners1.77%
Ins Owner Change-8.32%
Market Cap16.40B
Analysts78.1
Price Target412.24 (12.22%)
Short Float %4.6%
Short Ratio6.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-6.42%
Min EPS beat(2)-10.35%
Max EPS beat(2)-2.49%
EPS beat(4)2
Avg EPS beat(4)-0.92%
Min EPS beat(4)-10.35%
Max EPS beat(4)7.04%
EPS beat(8)5
Avg EPS beat(8)-2.72%
EPS beat(12)7
Avg EPS beat(12)-2.63%
EPS beat(16)8
Avg EPS beat(16)-8.19%
Revenue beat(2)2
Avg Revenue beat(2)1.46%
Min Revenue beat(2)1.3%
Max Revenue beat(2)1.61%
Revenue beat(4)4
Avg Revenue beat(4)3.51%
Min Revenue beat(4)1.3%
Max Revenue beat(4)6.48%
Revenue beat(8)6
Avg Revenue beat(8)2.1%
Revenue beat(12)8
Avg Revenue beat(12)1.8%
Revenue beat(16)12
Avg Revenue beat(16)2.86%
PT rev (1m)1.08%
PT rev (3m)5.06%
EPS NQ rev (1m)-3.56%
EPS NQ rev (3m)-3.56%
EPS NY rev (1m)1.56%
EPS NY rev (3m)1.53%
Revenue NQ rev (1m)-0.7%
Revenue NQ rev (3m)-0.7%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)-0.17%
Valuation
Industry RankSector Rank
PE 16.13
Fwd PE 13.01
P/S 5.95
P/FCF 18.26
P/OCF 14.43
P/B 2.69
P/tB 2.74
EV/EBITDA 8.27
EPS(TTM)22.77
EY6.2%
EPS(NY)28.25
Fwd EY7.69%
FCF(TTM)20.12
FCFY5.48%
OCF(TTM)25.46
OCFY6.93%
SpS61.74
BVpS136.67
TBVpS134.16
PEG (NY)0.58
PEG (5Y)2
Profitability
Industry RankSector Rank
ROA 15.6%
ROE 18.21%
ROCE 21.57%
ROIC 16.59%
ROICexc 35.46%
ROICexgc 36.88%
OM 48.91%
PM (TTM) 40.31%
GM 88.94%
FCFM 32.58%
ROA(3y)11.66%
ROA(5y)8.69%
ROE(3y)14.55%
ROE(5y)11.01%
ROIC(3y)12.87%
ROIC(5y)12.67%
ROICexc(3y)23.93%
ROICexc(5y)23.04%
ROICexgc(3y)24.48%
ROICexgc(5y)24.06%
ROCE(3y)16.74%
ROCE(5y)16.48%
ROICexcg growth 3Y12.25%
ROICexcg growth 5Y-6.96%
ROICexc growth 3Y13.45%
ROICexc growth 5Y-5.63%
OM growth 3Y8.46%
OM growth 5Y0.63%
PM growth 3Y6.83%
PM growth 5Y3.17%
GM growth 3Y-1.38%
GM growth 5Y0.26%
F-Score8
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.45
Debt/EBITDA 0
Cap/Depr 358.65%
Cap/Sales 8.65%
Interest Coverage 28.56
Cash Conversion 80.35%
Profit Quality 80.84%
Current Ratio 4.58
Quick Ratio 4.41
Altman-Z 12.52
F-Score8
WACC9.56%
ROIC/WACC1.74
Cap/Depr(3y)315.24%
Cap/Depr(5y)249.39%
Cap/Sales(3y)8.08%
Cap/Sales(5y)6.8%
Profit Quality(3y)89.17%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.45%
EPS 3Y19.66%
EPS 5Y8.08%
EPS Q2Q%18.77%
EPS Next Y27.89%
EPS Next 2Y19.32%
EPS Next 3Y14.52%
EPS Next 5Y22.25%
Revenue 1Y (TTM)25.04%
Revenue growth 3Y16.2%
Revenue growth 5Y7.41%
Sales Q2Q%22.89%
Revenue Next Year25.46%
Revenue Next 2Y17.71%
Revenue Next 3Y13.85%
Revenue Next 5Y11.32%
EBIT growth 1Y21.28%
EBIT growth 3Y26.04%
EBIT growth 5Y8.09%
EBIT Next Year27.31%
EBIT Next 3Y12.63%
EBIT Next 5Y1.04%
FCF growth 1Y32.27%
FCF growth 3Y2.39%
FCF growth 5Y4.71%
OCF growth 1Y33.89%
OCF growth 3Y8.98%
OCF growth 5Y4.67%